(SZYM) & Natura Announce Sales Agreement for Microalgae Oil

Natura Cosméticos S.A. (BM&FBOVESPA:NATU3) one of Latin America’s largest cosmetics and personal care products company, and Solazyme, Inc. (NASDAQ:SZYM), a renewable oils and ingredients company, announced today that after successfully completing testing and product validation phases over the past year using Solazyme’s oils, Natura is purchasing Solazyme’s high-performance AlgaPūr^TM Microalgae Oil, which will be incorporated into Natura’s multiple product lines.

Solazyme’s microalgae oils are produced in a matter of days using a fermentation process designed to produce oils of the highest purity, performance and sustainability. Some of the benefits of using AlgaPūr oils for skin care are higher hydration levels, a silky but not greasy skin feel, mildness on the skin, neutral color and odor, and improved shelf life.

Walfredo Linhares, General Manager of Solazyme Bunge Renewable Oils in Brazil, said, “We believe high performance and sustainability belong together. Natura is a leader in innovation and globally recognized for their sustainability efforts. We are very happy to work together to deliver better products for consumers and for our planet.”

Natura and Solazyme have been working together for two years on several projects on joint efforts to develop new formulations with Solazyme’s microalgae oils. “We are always looking for ingredients from renewable sources and technologies inspired in the nature, targeting low environmental impact processes and high performance solutions,” says Daniel Gonzaga, Director of Advanced Research of Natura. “Solazyme microalgae oil that will compose some of our products are a sustainable alternative for new formulations development,” he concludes.

Solazyme produces sustainable high performance ingredients for multiple markets and its joint venture facility is located in São Paulo State, in partnership with Bunge.

About Solazyme, Inc.

Solazyme, Inc. develops and sells high-performance oils and ingredients that are better for people and better for the planet. Starting with microalgae, the world’s original oil producer, Solazyme creates innovative, sustainable, high-performance products. These include renewable oils and ingredients that serve as the foundation for healthier foods; high-performance industrial products; unique home and personal care solutions; and more sustainable fuels. Headquartered in South San Francisco, Solazyme’s mission is to solve some of the world’s biggest problems with one of the world’s smallest and earliest life forms: microalgae.

For additional information, please visit Solazyme’s website at www.solazyme.com.

About Natura

Founded in 1969, Natura is the biggest Brazilian multinational of cosmetics and health and beauty products. Leader in the direct sales industry in Brazil, it reported net revenue totaling R$ 7.4 billion in 2014, it has 7,000 employees, 1.7 million consultants and operations in Argentina, Bolivia, Chile, Mexico, Peru, Colombia and France.

Largest B Corp company in the world, it was the first publicly-held company to receive the certification, in December 2014, which reinforces its transparent and sustainable operations on social, environmental and economic aspects. The company’s structure is made up of plants in Cajamar (SP) and Benevides (PA), eight distribution centers in Brazil, one HUB in Itupeva, in addition to Research and Technology centers in São Paulo (SP), Manaus (AM) and New York (USA). It holds 65% of the Australian manufacturer of cosmetics Aesop, with stores in countries in Oceania, Asia, Europe and North America. Natura’s products can be purchased through Revista Natura (product catalog) or Rede Natura at www.redenatura.net. To find a Natura Consultant nearby, consumers can send a free SMS with the word for Natura 28128. For more information about the company, visit www.natura.com.br and check their profiles on the following social networks: Linkedin, Facebook, Twitter and YouTube.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Solazyme, including statements that involve risks and uncertainties concerning: its commercialization and production plans; meeting commercialization and technology targets; successful product trials and market acceptance of its products; and Solazyme’s ability to maintain its relationships with its partners. When used in this press release, the words “will”, “expects”, “intends” and other similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Solazyme, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this press release due to a number of risks and uncertainties. Potential risks and uncertainties include, among others: Solazyme’s limited operating history; its limited history in commercializing products; implementation risk in deploying new technologies; its limited experience in constructing, ramping up and operating commercial manufacturing facilities; its ability to sell its products at a profit; delays related to construction, start-up and ramp-up of production facilities; its ability to manage operational costs at production facilities; its ability to enter into and maintain strategic collaborations; its ability to obtain requisite regulatory approvals; and its access, on favorable terms, to any required financing. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Solazyme.

In addition, please refer to the documents that Solazyme, Inc. files with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q, as updated from time to time, for a discussion of these and other risks. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. Solazyme is not under any duty to update any of the information in this press release.

Solazyme, Inc.
Genet Garamendi, 650-780-4777
Corporate Communications
press@solazyme.com